Eli Lilly and Company

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Amprion is a biotechnology company specializing in the development of diagnostic tests for brain diseases. Founded in 2007, it is headquartered in San Francisco, California. The company focuses on detecting pathological α-synuclein in cerebrospinal fluid to aid clinicians in diagnosing neurodegenerative conditions like Parkinson's and Lewy body dementia.

RetiSpec is developing a non-invasive eye scanner for the early detection of Alzheimer’s Disease pathology years before symptoms occur. This enables clinicians to intervene with emerging therapeutics at an earlier stage when there's a chance of impacting the disease.

Zephyr AI is a healthcare technology company focused on transforming drug discovery and precision medicine. By leveraging large complex datasets and proprietary algorithms, Zephyr AI aims to redefine drug development and streamline clinical trials. The company collaborates with leading health systems, health insurance plans, and biotechnology innovators to enhance healthcare quality, improve patient outcomes, and reduce costs. Through its innovative approach, Zephyr AI seeks to address challenges in disease treatment and clinical decision support, ultimately contributing to advancements in the healthcare sector.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Beijing Targeting One Technology Co., Ltd. specializes in the development and production of biomedical instruments and consumables, focusing on in vitro diagnostic reagents for precision medicine, health management, and life science research. Established in 2015 and based in Beijing, the company offers a range of products including sample preparation apparatus, biochip readers, digital PCR supplies, and genetic testing kits. Its digital PCR solutions play a crucial role in medical diagnostics, with applications in transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Targeting One aims to enhance gene testing and precision medicine through its innovative technologies and comprehensive offerings.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Akura Medical develops next-generation thrombectomy devices designed to simplify clot removal with a single-pass procedure, offering an easy-to-use solution to efficiently remove blood clots. The company also provides a range of surgical, medical, dental, and veterinary instruments to support clinicians in addressing venous thromboembolism and other clot-related conditions across diverse patient populations.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.

Duality Biologics is a biopharmaceutical company focused on oncology and autoimmune diseases, developing novel modality drugs that include antibody-drug conjugates and bispecific antibodies. It operates a sizable internal pipeline of ADCs and bispecific candidates, with multiple programs in clinical development and several preclinical assets. The company has built a next-generation ADC platform with broad global intellectual property rights and aims to translate novel modalities into approved therapies. Its pipeline comprises numerous in-house ADC candidates, including seven clinical-stage ADCs and two next-generation bispecific ADCs, with additional preclinical programs, and some assets have received regulatory designations such as Fast Track.

Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.

Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

Beijing Targeting One Technology Co., Ltd. specializes in the development and production of biomedical instruments and consumables, focusing on in vitro diagnostic reagents for precision medicine, health management, and life science research. Established in 2015 and based in Beijing, the company offers a range of products including sample preparation apparatus, biochip readers, digital PCR supplies, and genetic testing kits. Its digital PCR solutions play a crucial role in medical diagnostics, with applications in transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Targeting One aims to enhance gene testing and precision medicine through its innovative technologies and comprehensive offerings.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Rimidi Inc. is a healthcare technology company focused on improving diabetes management for patients and healthcare providers. Founded in 2011 and based in Atlanta, Georgia, Rimidi develops a cloud-based software solution called DIABETES+ME, which integrates patient-generated health data from connected devices with clinical data to identify gaps in diabetes care. This platform allows physicians to monitor patients remotely, providing insights that facilitate timely interventions and treatment adjustments. By promoting effective communication and data-driven decision-making, Rimidi aims to enhance the overall management of diabetes, addressing a critical issue in healthcare. The company was formerly known as Rimidi Diabetes, Inc. and rebranded in July 2018.

Singlera Genomics Inc. is a biotechnology company that specializes in genetic testing and molecular diagnostic technologies. Founded in 2014 and headquartered in La Jolla, California, with additional operations in Shanghai, China, Singlera develops a methylation detection platform designed for early cancer diagnosis and prevention. The company offers a range of services, including tumor diagnosis, personalized treatment, non-invasive prenatal diagnosis, and pre-implantation genetic screening. Additionally, Singlera is focused on advancing precision medicine, aiming to provide patients with early, accurate, and informative diagnostic solutions to improve healthcare outcomes.

Entrega Bio is a Boston-based company that specializes in developing a proprietary hydrogel technology aimed at improving the oral delivery of injectable substances, including biologics, vaccines, and other medications that typically face absorption challenges. This innovative platform allows for the creation of customizable oral dosage forms that enhance the stability and absorption of large and unstable drug molecules by effectively controlling the gastrointestinal fluid microenvironment. By collaborating with both pharmaceutical and non-pharmaceutical partners, Entrega Bio aims to advance therapeutic and diagnostic applications across various fields, including disease management and mobile health.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Singlera Genomics Inc. is a biotechnology company that specializes in genetic testing and molecular diagnostic technologies. Founded in 2014 and headquartered in La Jolla, California, with additional operations in Shanghai, China, Singlera develops a methylation detection platform designed for early cancer diagnosis and prevention. The company offers a range of services, including tumor diagnosis, personalized treatment, non-invasive prenatal diagnosis, and pre-implantation genetic screening. Additionally, Singlera is focused on advancing precision medicine, aiming to provide patients with early, accurate, and informative diagnostic solutions to improve healthcare outcomes.

360 Haoyao is an online pharmacy marketplace. 360 Haoyao is committed to creat a simple, convenient and trusted health product shopping experience. In order to safeguard its health, 360 Good Medicine connects the healthcare industry and relies on 360 strong technical capabilities to provide credible and feasible medical and e-commerce services, medical information services and "Internet +" technology solutions to Chinese Internet users and the pharmaceutical industry. Establish an industrial service system to promote the utilization of medical resources and promote the improvement of health management of all people.

Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources. It focuses on addressing significant health challenges, particularly resistant infectious diseases and cancers, by collaborating with global pharmaceutical companies and leading non-governmental organizations. Founded to realize the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo Therapeutics utilizes a genome-based, culture-independent platform to discover and characterize small molecules sourced from environmental microbial DNA. This innovative approach leverages advancements in DNA sequencing and bioinformatics to explore the untapped potential of microbial evolution, aiming to identify therapeutically valuable pharmaceutical products. Headquartered in New York City at the Alexandria Center for Life Science, Lodo Therapeutics is committed to harnessing the power of nature in the fight against undruggable targets and high unmet medical needs.

Caldan Therapeutics is a spinout from the University of Glasgow and the University of Southern Denmark focused on developing therapeutics that modulate free fatty acid receptors to address metabolic diseases, including Type 2 Diabetes, with potential applications in non-alcoholic steatohepatitis and inflammatory conditions. Building on a long-term collaboration between leading researchers, the company seeks to target multiple aspects of diabetes pathology, such as insulin secretion, insulin sensitivity, and islet cell protection, while aiming to reduce inflammatory activity in muscle, liver, and adipose tissue. The approach centers on delivering glucose-lowering effects by modulating receptor pathways implicated in diabetes and related inflammatory diseases.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

HD Biosciences Inc. is a biotechnology company based in Shanghai, specializing in contract research for drug discovery. As a subsidiary of WuXi PharmaTech, it offers a comprehensive suite of services including assay development, high-throughput drug screening, structure-activity relationship analysis, and hit-to-lead biology solutions. The company has developed advanced technology platforms for drug discovery and has established long-term research agreements with major pharmaceutical clients, including Pfizer and Organon. HD Biosciences is recognized as a leader in biology-based drug discovery services in China, providing a range of capabilities from hit identification to in vivo pharmacology, thereby supporting the development of innovative pharmaceutical and biotechnology solutions.

Standard BioTools develops, manufactures, and sells technologies that accelerate biomedical research and medicines development. The company provides standardized, next-generation tools built around proprietary mass cytometry and microfluidics platforms to generate reliable insights into health and disease. Its proteomics and genomics capabilities support a range of applications in translational and clinical research, including oncology, immunology, and immunotherapy. The products are used by academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. By delivering repeatable measurement platforms, Standard BioTools helps researchers translate discoveries into improved patient outcomes.

EyeTel Imaging, founded in 1996, specializes in developing advanced imaging technologies aimed at preventing vision loss associated with undetected diabetic retinopathy. The company's flagship product, the EyeTel Retinal Imaging System, utilizes the DigiScope, a semi-automated fundus camera that captures high-quality images, facilitating the detection of various ocular conditions, including age-related macular degeneration and glaucoma. EyeTel also operates the EyeTel Reading Center, a telemedicine service that offers expert analysis of patient images by trained specialists, ensuring accurate diagnoses. Collaborating with the Wilmer Eye Institute and manufacturing partner Topzone in China, EyeTel has successfully enhanced its retinal imaging capabilities while maintaining a commitment to cost-effectiveness and ease of use. The technology is clinically validated and designed for primary care settings, reflecting the company's dedication to improving patient care in a convenient manner.

Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.

NexCura is a provider of online decision support services aimed at enhancing communication between patients and physicians. The company's applications and custom services are offered through an application service provider model, enabling the collection of comprehensive clinical data. NexCura's tools include the NexProfiler, which integrates clinical evidence with personal concerns and individual patient circumstances to assist in pre-treatment decision-making. Additionally, the company offers patient education and market research services, delivering valuable insights to healthcare organizations, pharmaceutical companies, physicians, and patients alike.

Pacific Biotech develops and markets diagnostic tests for detection of pregnancy, infectious diseases, strep throat, and mononucleosis.